Get the Stockscreener App
4.83
3.87%
0.18
After Hours:
4.80
-0.03
-0.62%
Onconetix Inc stock is traded at $4.83, with a volume of 185.84K.
It is up +3.87% in the last 24 hours and down -21.51% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$4.65
Open:
$4.65
24h Volume:
185.84K
Relative Volume:
0.72
Market Cap:
$42,688
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.0444
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
+15.27%
1M Performance:
-21.51%
6M Performance:
-85.24%
1Y Performance:
-99.31%
1-Day Range:
$4.65
$5.10
1-Week Range:
$3.97
$5.10
52-Week Range:
$3.82
$1,190.00
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
4.83 | 42,688 | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Onconetix Inc Stock (ONCO) Latest News
Onconetix Secures Nasdaq Listing with Panel Decision - TipRanks
Onconetix receives positive decision by Nasdaq Hearings Panel - TipRanks
Onconetix regains Nasdaq compliance after filing Q1 report - Investing.com
Onconetix, Inc. Announces Positive Decision By Nasdaq Hearings Panel - MarketScreener
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewswire
Onconetix Avoids Nasdaq Delisting: Key Panel Decision Keeps Biotech Stock Listed - Stock Titan
Onconetix, Inc. SEC 10-Q Report - TradingView
Onconetix to implement 1-for-85 reverse stock split effective June 13 By Investing.com - Investing.com South Africa
Onconetix Issues Promissory Note to Keystone Capital - TipRanks
Onconetix to implement 1-for-85 reverse stock split effective June 13 - Investing.com Nigeria
Onconetix Announces 1-For-85 Reverse Stock Split - marketscreener.com
Onconetix to Implement 1-for-85 Reverse Stock Split - marketscreener.com
Onconetix announces 1-for-85 reverse stock split - MSN
Onconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by Stockholders - Nasdaq
Spotify Stock Soars 124% in a Year: Time to Buy, Hold or Fold? - The Globe and Mail
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewswire
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of ... - Bluefield Daily Telegraph
Onconetix Implements Massive 1:85 Reverse Split, Slashing Shares from 44M to 521K to Save Nasdaq Listing - Stock Titan
1 Monster Growth Stock That's Crushing the Market in 2025 - The Globe and Mail
Onconetix Stockholders Approve Reverse Stock Split Proposal - TipRanks
1 ETF to Buy Hand Over Fist to Follow the TACO Trade - The Globe and Mail
Tariffs Aren't O'Reilly's Biggest Problem, This Is - The Globe and Mail
Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Onconetix, Inc. SEC 10-K Report - TradingView
Leading Industrial Manufacturer Selects HawkSearch to Power Digital Commerce Growth - The Globe and Mail
Onconetix receives additional delisting notice from Nasdaq - Yahoo Finance
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - The Manila Times
Onconetix faces potential Nasdaq delisting over filing delays By Investing.com - Investing.com Nigeria
Onconetix receives additional notice from Nasdaq - MSN
Onconetix Faces Nasdaq Delisting Notice Amid Compliance Issues - TipRanks
Onconetix faces potential Nasdaq delisting over filing delays - Investing.com Australia
Onconetix, Inc. Receives Nasdaq Delisting Letter for Failure to File Quarterly Report and Maintain Minimum Bid Price Requirements - Nasdaq
Onconetix Faces Triple Threat: Nasdaq Delisting Risk Over Missing Filings and 10-Cent Stock Price - Stock Titan
Noram Receives Results for CVZ-66: High of 1540 ppm Intersection of 220ft (67.1 m) Averaging 1124 ppm of Lithium - The Globe and Mail
ONCOOnconetix Latest Stock News & Market Updates - Stock Titan
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - Barchart.com
Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan
Onconetix Inc [ONCO] Is Currently 14.45 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Onconetix Inc (ONCO) expanding its growth trajectory ahead - Sete News
ONCO Stock on the Rise: A Promising Investment - investchronicle.com
This morning’s top pick is Onconetix Inc (NASDAQ:ONCO) - uspostnews.com
Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News
ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form 8-KCurrent report - ADVFN
Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals
Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India
Onconetix faces Nasdaq delisting over low share price - Investing.com
ONCO’s current quarter earnings: What analysts forecast? - uspostnews.com
ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):